Circulating proteins as predictors of incident heart failure in the elderly

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European Journal of Heart Failure

• Publication date

  2018-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ejhf.980PMID 28967680
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2016 European Guidelines on cardiovascular disease prevention in clinical practice

  2017cited by this paper
• Endoplasmic reticulum stress associated apoptosis implicated in atrial fibrillation

  2016cited by this paper
• Urine proteome analysis in heart failure with reduced ejection fraction complicated by chronic kidney disease: feasibility, and clinical and pathogenetic correlates

  2016cited by this paper
• The utility of biomarker risk prediction score in patients with chronic heart failure

  2016cited by this paper
• Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip

  2015cited by this paper
• Soluble Urokinase Receptor and Chronic Kidney Disease.

  2015cited by this paper
• Population Risk Prediction Models for Incident Heart Failure: A Systematic Review

  2015cited by this paper
• Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis.

  2015cited by this paper
• The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease

  2015cited by this paper
• The utility of biomarker risk prediction score in patients with chronic heart failure.

  2015cited by this paper
• 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• A pilot study of angiogenin in heart failure with preserved ejection fraction: a novel potential biomarker for diagnosis and prognosis?

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation

  2014cited by this paper
• Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

  2014cited by this paper
• Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study).

  2014cited by this paper
• Large-scale gene function analysis with the PANTHER classification system

  2013cited by this paper
• Urinary kidney injury molecule 1 and incidence of heart failure in elderly men

  2013cited by this paper
• Heart failure.

  2013cited by this paper
• Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study

  2012cited by this paper
• Inflammatory biomarkers as risk factors for future atrial fibrillation. An eleven-year follow-up of 6315 men and women: the Tromsø study.

  2012cited by this paper
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice

  2012cited by this paper
• Prediction of Incident Heart Failure in General Practice: The Atherosclerosis Risk in Communities (ARIC) Study

  2012cited by this paper
• Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood

  2011cited by this paper
• DAGitty: a graphical tool for analyzing causal diagrams.

  2011cited by this paper
• Clinical outcome of renal tubular damage in chronic heart failure.

  2011cited by this paper
• Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy

  2010cited by this paper
• European Guidelines on Cardiovascular Disease Prevention

  2009cited by this paper
• Genetic Dissection of a Blood Pressure Quantitative Trait Locus on Rat Chromosome 1 and Gene Expression Analysis Identifies SPON1 As a Novel Candidate Hypertension Gene

  2007cited by this paper
• Searching for biomarkers of heart failure in the mass spectra of blood plasma

  2006cited by this paper
• A Comparison of Three Different Methods to Evaluate Endothelium-Dependent Vasodilation in the Elderly: The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study

  2005cited by this paper
• [Effect of shengmai injection on TRAIL death receptor of patients with congestive heart failure].

  2005cited by this paper
• The validity of a diagnosis of heart failure in a hospital discharge register

  2005cited by this paper
• Mining biomarkers in human sera using proteomic tools

  2004cited by this paper
• Clinical epidemiology of heart failure: public and private health burden.

  1998cited by this paper
• Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology.

  1995cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper
• A study of middle-aged men with particular reference to risk factors for cardiovascular disease.

  1975cited by this paper
• Heart Failure

  1937cited by this paper

• Olink Proteomics in Heart Failure: A Comprehensive Review of Applications From Biomarker Discovery to Pathophysiological Insights and Clinical Implementation

  2026influential citation
• Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure.

  2026cites this paper
• Large-Scale Proteomic Profiling of Incident Heart Failure and Its Subtypes in Older Adults.

  2026cites this paper
• Clinical Insights from Proteomics in Heart Failure

  2025cites this paper
• The Dual Role of the TRAIL-DR5 Signaling Axis in Cardiovascular Disease: From Molecular Mechanisms to Targeted Therapies

  2025influential citation
• TRAIL and RIPK3 Do Not Predict Mortality and Acute Kidney Injury in Critically Ill Patients at Admission to the Intensive Care Unit—A Single-Center Cohort Study

  2025cites this paper
• Heart Failure Prediction in Dysglycemia: Are We Ready to Trust the Proteome?

  2025cites this paper
• Causal Associations of Cardiovascular Proteins and Diabetic Nephropathy Revealed by Mediation and Phenome-Wide Mendelian Randomization

  2025cites this paper
• Death receptor 5 agonists mitigate cardiac pathology in a chronic isoproterenol-induced cardiac remodeling and dysfunction.

  2025cites this paper
• Association of TNF-R1 with Exercise Capacity in Asymptomatic Hypertensive Heart Disease—Mediating Role of Left Ventricular Diastolic Function Deterioration

  2025cites this paper
• Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy

  2025cites this paper
• The EAT-Lancet Diet Index, Plasma Proteins, and Risk of Heart Failure in a Population-Based Cohort.

  2024cites this paper
• Beyond Natriuretic Peptides: Unveiling the Power of Emerging Biomarkers in Heart Failure

  2024cites this paper
• Proteomic Associations of Adverse Outcomes in Human Heart Failure

  2024cites this paper
• Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure

  2024cites this paper
• Predicting heart failure: The promise of proteomics

  2024cites this paper
• Large scale plasma proteomics identifies novel proteins and protein networks associated with heart failure development

  2024influential citation
• Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts

  2024cites this paper
• Comprehensive Proteomics Profiling Identifies Circulating Biomarkers to Distinguish Hypertrophic Cardiomyopathy From Other Cardiomyopathies With Left Ventricular Hypertrophy

  2024cites this paper
• Clinical-transcriptional prioritization of the circulating proteome in human heart failure

  2024cites this paper
• Application of proteomics for novel drug discovery and risk prediction optimisation in stroke and myocardial infarction: a review of in-human studies.

  2024cites this paper
• Relationship of proteins and subclinical cardiovascular traits in the population-based LIFE-Adult study.

  2024cites this paper
• Measured and genetically predicted protein levels and cardiovascular diseases in UK Biobank and China Kadoorie Biobank

  2024cites this paper
• Ancestrally diverse genome-wide association analysis highlights ancestry-specific differences in genetic regulation of plasma protein levels

  2024cites this paper
• Plasma proteome and incident myocardial infarction: sex-specific differences

  2024cites this paper
• Bioinformatics and machine learning approaches reveal key genes and underlying molecular mechanisms of atherosclerosis: A review

  2024cites this paper
• Using Omics to Identify Novel Therapeutic Targets in Heart Failure

  2024cites this paper
• Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

  2023cites this paper
• Are the results from a multiplex proteomic assay and a conventional immunoassay for NT-proBNP and GDF-15 comparable?

  2023cites this paper
• Association of cardiac troponin T and growth differentiation factor 15 with replacement and interstitial cardiac fibrosis in community dwelling adults: The multi-ethnic study of atherosclerosis

  2023cites this paper
• Estimating the causal effects of genetically predicted plasma proteome on heart failure

  2023cites this paper
• Causal effects for genetic variants of osteoprotegerin on the risk of acute myocardial infarction and coronary heart disease: A two-sample Mendelian randomization study

  2023cites this paper
• The Prognostic, Diagnostic, and Therapeutic Potential of TRAIL Signalling in Cardiovascular Diseases

  2023cites this paper
• Apoptotic cell death in disease—Current understanding of the NCCD 2023

  2023cites this paper
• Proteomic prediction of incident heart failure and its main subtypes

  2023cites this paper
• Predictive biomarkers for the early detection and management of heart failure

  2023cites this paper
• Circulating Growth Differentiation Factors 11 and 8, Their Antagonists Follistatin and Follistatin-like-3, and Risk of Heart Failure in Elders.

  2023cites this paper
• Comorbidity of chronic heart failure and osteoporosis: literature review

  2023cites this paper
• TRAIL and its receptors in cardiac diseases

  2023influential citation
• Prediction models for heart failure in the community: A systematic review and meta‐analysis

  2023cites this paper
• Proteomic Pathways across Ejection Fraction Spectrum in Heart Failure: an EXSCEL Substudy

  2023cites this paper
• Single-Cell Dissection of the Immune Response After Acute Myocardial Infarction

  2023cites this paper
• Scenarios in precision medicine: proteomics in heart failure

  2022cites this paper
• TRAIL inhibition by soluble death receptor 5 protects against acute myocardial infarction in rats

  2022cites this paper
• A universal predictive and mechanistic urinary peptide signature in acute kidney injury

  2022cites this paper
• Inflammation and heart failure: a two-sample Mendelian randomization study

  2022cites this paper
• Heart failure in obesity: insights from proteomics in patients treated with or without weight-loss surgery

  2022cites this paper
• Screening for Biomarkers Associated with Left Ventricular Function During Follow-up After Acute Coronary Syndrome

  2022cites this paper
• Pathophysiology and Management of Chronic Heart Failure

  2022cites this paper
• A novel biomarker panel index improves risk stratification after ischemic stroke

  2022cites this paper
• A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk

  2022cites this paper
• Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization

  2022influential citation
• Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study

  2022cites this paper
• Physical Inactivity Is Associated With Post-discharge Mortality and Re-hospitalization Risk Among Swedish Heart Failure Patients—The HARVEST-Malmö Study

  2022cites this paper
• Tryptophan, after inflammatory cytokine stimulation, determines plaque vulnerability and risk of myocardial infarction

  2022cites this paper
• Dynamic personalized risk prediction in chronic heart failure patients: a longitudinal, clinical investigation of 92 biomarkers (Bio-SHiFT study)

  2022cites this paper
• Heart failure among patients with prediabetes and type 2 diabetes mellitus: diagnostic and predictive biomarkers: a narrative review

  2021cites this paper
• Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

  2021cites this paper
• Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study

  2021cites this paper
• Sleep duration is associated with protein biomarkers for cardiometabolic health: A large‐scale population study

  2021cites this paper
• TRAIL and Cardiovascular Disease—A Risk Factor or Risk Marker: A Systematic Review

  2021cites this paper
• Biomarkers for the diagnosis and management of heart failure

  2021cites this paper
• Genome-wide analysis of DNA methylation and risk of cardiovascular disease in a Chinese population

  2021cites this paper
• Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction

  2021cites this paper
• Plasma Protein Profile of Incident Myocardial Infarction, Ischemic Stroke, and Heart Failure in 2 Cohorts

  2021cites this paper
• Predicting outcome in acute myocardial infarction: an analysis investigating 175 circulating biomarkers.

  2021cites this paper
• Towards precision medicine in heart failure

  2021cites this paper
• Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation

  2021cites this paper
• The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE‐17 trial subanalysis

  2021cites this paper
• Associations between biomarkers of multimorbidity burden and mortality risk among patients with acute dyspnea

  2021cites this paper
• A Dual Role for Death Receptor 5 in Regulating Cardiac Fibroblast Function

  2021cites this paper
• Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial

  2021cites this paper
• Omics technologies in personalized combination therapy for cardiovascular diseases: challenges and opportunities.

  2021cites this paper
• Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes

  2021cites this paper
• Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults

  2021cites this paper
• Biomarkers of heart failure: current state of problem

  2021cites this paper
• Finding a Needle in a Haystack

  2020cites this paper
• Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction

  2020cites this paper
• Proteomic Signatures During Treatment in Different Stages of Heart Failure

  2020cites this paper
• Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention

  2020cites this paper
• Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease

  2020cites this paper
• Targeted multiplex proteomics for prediction of all-cause mortality during long-term follow-up in outpatients with peripheral arterial disease.

  2020cites this paper
• Association of Cardiac Biomarkers With the Kansas City Cardiomyopathy Questionnaire in Patients With Chronic Kidney Disease Without Heart Failure

  2020cites this paper
• Omics phenotyping in heart failure: the next frontier.

  2020cites this paper
• Multiplex Analysis of Circulating Maternal Cardiovascular Biomarkers Comparing Preeclampsia Subtypes

  2020cites this paper
• Blocking the death checkpoint protein TRAIL improves cardiac function after myocardial infarction in monkeys, pigs, and rats

  2020cites this paper
• Temporal patterns of macrophage‐ and neutrophil‐related markers are associated with clinical outcome in heart failure patients

  2020cites this paper
• Epidemiology of Physical Activity and Fragility Fractures

  2020cites this paper
• A MULTI-MARKER MODEL FOR PREDICTING DECOMPENSATED HEART FAILURE IN PATIENTS WITH PRIOR ACUTE MYOCARDIAL INFARCTION

  2020cites this paper
• Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning

  2020cites this paper
• Short‐term exposure to ambient air pollution and circulating biomarkers of endothelial cell activation: The Framingham Heart Study

  2019cites this paper
• Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.

  2019cites this paper
• Serum Proteomic Approach for Differentiation of Frail and Non-Frail Elderly

  2019cites this paper
• Monitoring of biomarkers in heart failure

  2019cites this paper
• ESC Heart Failure receives its first impact factor

  2019cites this paper
• Drug therapy in elderly heart failure patients

  2019cites this paper
• Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets

  2019cites this paper
• Is proteomics of value in cardiovascular risk assessment?

  2019cites this paper
• Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association.

  2019cites this paper
• Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation.

  2019cites this paper